Pacific Edge Ltd
NZX:PEB
Intrinsic Value
Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. [ Read More ]
The intrinsic value of one PEB stock under the Base Case scenario is 0.668 NZD. Compared to the current market price of 0.084 NZD, Pacific Edge Ltd is Undervalued by 87%.
Valuation Backtest
Pacific Edge Ltd
Run backtest to discover the historical profit from buying and selling PEB stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Pacific Edge Ltd
Current Assets | 70.8m |
Cash & Short-Term Investments | 62.2m |
Receivables | 5.2m |
Other Current Assets | 3.4m |
Non-Current Assets | 5.5m |
PP&E | 4.3m |
Intangibles | 1.2m |
Current Liabilities | 7.1m |
Accounts Payable | 6.5m |
Other Current Liabilities | 529k |
Non-Current Liabilities | 884k |
Long-Term Debt | 884k |
Earnings Waterfall
Pacific Edge Ltd
Revenue
|
24m
NZD
|
Operating Expenses
|
-59.2m
NZD
|
Operating Income
|
-35.2m
NZD
|
Other Expenses
|
3.6m
NZD
|
Net Income
|
-31.6m
NZD
|
Free Cash Flow Analysis
Pacific Edge Ltd
PEB Profitability Score
Profitability Due Diligence
Pacific Edge Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
Score
Pacific Edge Ltd's profitability score is 32/100. The higher the profitability score, the more profitable the company is.
PEB Solvency Score
Solvency Due Diligence
Pacific Edge Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Pacific Edge Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PEB Price Targets Summary
Pacific Edge Ltd
According to Wall Street analysts, the average 1-year price target for PEB is 0.153 NZD with a low forecast of 0.131 NZD and a high forecast of 0.168 NZD.
Shareholder Return
PEB Price
Pacific Edge Ltd
Average Annual Return | 188.23% |
Standard Deviation of Annual Returns | 448.5% |
Max Drawdown | -95% |
Market Capitalization | 68.1m NZD |
Shares Outstanding | 811 271 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Pacific Edge Ltd. engages in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. The firm develops and commercializes diagnostic and prognostic tools for the early detection and management of cancers. The firm's segments include NZ Laboratory, US Laboratory and Research NZ & Australia. Its segments are engaged in the research and development of diagnostic and prognostic products for human cancer both in New Zealand and Australia, and operation of the laboratories used for the detection of bladder cancer in the United States and New Zealand. The company offers Cxbladder, which is a suite of non-invasive laboratory tests for the detection and the management of bladder cancer. Cxbladder includes a suite of urine-based molecular tests to determine the likelihood of bladder cancer in patients presenting with hematuria. Its pipeline includes Cxcolorectal, which is a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancer, enabling prediction of aggressiveness of the tumor.
Contact
IPO
Employees
Officers
The intrinsic value of one PEB stock under the Base Case scenario is 0.668 NZD.
Compared to the current market price of 0.084 NZD, Pacific Edge Ltd is Undervalued by 87%.